Approach

Galapagos has discovered drug targets (starting points for the development of novel drugs) using cells from patients for more than fifteen diseases. These targets form the basis of drug discovery programs aimed at identifying small molecules or antibodies that alter the activity of these proteins, thereby potentially changing the course of the disease.  By studying the disease process and key points of intervention, it is our goal to develop new drugs that stop the disease rather than just treat the symptoms.

Download target discovery guide

Galapagos made the strategic decision to pursue drug discovery and development in orphan diseases – diseases of high medical need, not commonly pursued by pharmaceutical companies. Cystic fibrosis (CF) is the first orphan disease in which Galapagos plans to discover, develop and launch disease-modifying medicines. This decision is based on Galapagos’ successful collaboration with the CF Foundation. With this strategy, Galapagos expects to benefit from the accelerated approval procedures and exclusive commercial rights granted to developers of orphan drugs through US and European regulatory agencies, to ultimately provide real medical benefit to this sizeable population of patients.

In November 2008, Galapagos and MorphoSys initiated an alliance to co-develop novel therapeutic antibodies in bone & joint disease. The partners combine their proprietary drug targets and unique technologies to discover and develop antibody therapies based on novel modes of action in bone & joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis. Both companies will share the research and development costs, as well as all future revenues equally.

Antibodies with high specificity towards the first target have been generated and are now being tested in disease-specific experiments. In parallel, Galapagos has applied its target discovery platform to identify additional targets for antibody development.

Share to Facebook Share to Twitter Share to LinkedIn Share via Email

© Copyright 2013 Galapagos NV | Disclaimer | General Purchase Terms 

Related publications

 Quantification Assays for Total and Polyglutamine-Expanded Huntingtin Proteins
Douglas Macdonald, Michela A. Tessari, Ivette Boogaard, Melanie Smith, Kristiina Pulli, Agnieszka Szynol, Faywell Albertus, Marieke B. A. C. Lamers, Sipke Dijkstra, Daniel Kordt, Wolfgang Reindl, Frank Herrmann, George McAllister, David F. Fischer, Ignacio Munoz-Sanjuan
PLoS ONE 9(5): e96854. doi:10.1371/journal.pone.0096854

 Biology calls the targets: combining RNAi and disease biology
van Es HH, Arts GJ
Drug Discov Today 2005 Oct 15;10(20):1385-91

 Functional screening of viral siRNA libraries in human primary cells
Bortone K, Michiels F, Vandeghinste N, Tomme P, and van Es H.
Drug Discov World 2004 Fall:20-27

 Adenoviral vectors expressing siRNAs for discovery and validation of gene function
Arts GJ, Langemeijer E, Tissingh R, Ma L, Pavliska H, Dokic K, Dooijes R, Mesic E, Clasen R, Michiels F, van der Schueren J, Lambrecht M, Herman S, Brys R, Thys K, Hoffmann M, Tomme P, van Es H
Genome Res. 2003 Oct;13(10):2325-32

 Arrayed adenoviral expression libraries for functional screening
Michiels F, van Es H, van Rompaey L, Merchiers P, Francken B, Pittois K, van der Schueren J, Brys R, Vandersmissen J, Beirinckx F, Herman S, Dokic K, Klaassen H, Narinx E, Hagers A, Laenen W, Piest I, Pavliska H, Rombout Y, Langemeijer E, Ma L, Schipper C, Raeymaeker MD, Schweicher S, Jans M, van Beeck K, Tsang IR, van de Stolpe O, Tomme P, Arts GJ, Donker J
Nat Biotechnol. 2002 Nov;20(11):1154-7. Erratum in: Nat Biotechnol. 2003 Feb;21(2):199

 
Test